Skip to main content
Top
Published in: Supportive Care in Cancer 9/2016

01-09-2016 | Original Article

Oncologists’ experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis

Authors: Güthlin Corina, Holmberg Christine, Gudrun Klein

Published in: Supportive Care in Cancer | Issue 9/2016

Login to get access

Abstract

Purpose

The rising use of complementary and alternative medicine (CAM) means oncologists are increasingly asked by patients to discuss CAM treatment options. However, no formal training or established standards are available on the subject. The aim of this paper was to investigate real-world discussions of CAM treatments. In particular, we wanted to learn about the values, norms and defining features that characterise oncologist-patient discussions on CAM.

Methods

Semi-standardised interviews with 17 oncologists were analysed using interpretation pattern analysis combined with thematic analysis.

Results

Advice on CAM is seen by oncologists as an important service they provide to their patients, even though their knowledge of the subject is often limited. Many interviewees mentioned an apparent lack of scientific proof, especially when their aim was to warn patients against the use of CAM. Discussions on CAM tend to reflect the idea that CAM belongs ‘to another world’, and judging by the interviews with oncologists, this notion appears to be shared by patients and oncologists alike.

Conclusions

Oncologists require reliable information on CAM and would profit from training in the communication of CAM treatment options to patients. Knowing scientific data on CAM would also lower barriers stemming from the view that CAM belongs ‘to another world’. Under- and postgraduate education programmes should include training on how to respond to requests addressing possible CAM options.
Literature
1.
go back to reference Ashikaga T, Bosompra K, O’Brien P, et al. (2002) Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer 10(7):542–548CrossRefPubMed Ashikaga T, Bosompra K, O’Brien P, et al. (2002) Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer 10(7):542–548CrossRefPubMed
2.
go back to reference Horneber M, Bueschel G, Dennert G, et al. (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187–203CrossRefPubMed Horneber M, Bueschel G, Dennert G, et al. (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187–203CrossRefPubMed
3.
go back to reference Baum M, Cassileth B, Daniel R, et al. (2006) The role of complementary and alternative medicine in the management of early breast cancer: recommendations of the European Society of Mastology (EUSOMA). Eur J Cancer 42:1711–1714CrossRefPubMed Baum M, Cassileth B, Daniel R, et al. (2006) The role of complementary and alternative medicine in the management of early breast cancer: recommendations of the European Society of Mastology (EUSOMA). Eur J Cancer 42:1711–1714CrossRefPubMed
4.
go back to reference Frenkel M, Ben-Arye E, Cohen L, et al. (2010) Communication in cancer care: discussing complementary and alternative medicine. Integr Cancer Ther 9(2):177–185CrossRefPubMed Frenkel M, Ben-Arye E, Cohen L, et al. (2010) Communication in cancer care: discussing complementary and alternative medicine. Integr Cancer Ther 9(2):177–185CrossRefPubMed
5.
go back to reference Braun L, Harris J, Katris P, et al. (2014) Clinical Oncology Society of Australia position statement on the use of complementary and alternative medicine by cancer patients. Asia-Pacific J Clin Oncol 10(4):289–296. doi:10.1111/ajco.12227 CrossRef Braun L, Harris J, Katris P, et al. (2014) Clinical Oncology Society of Australia position statement on the use of complementary and alternative medicine by cancer patients. Asia-Pacific J Clin Oncol 10(4):289–296. doi:10.​1111/​ajco.​12227 CrossRef
6.
go back to reference Schofield P, Diggens J, Charleson C, et al. (2010) Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians. Pat Edu Couns 79(2):143–151CrossRef Schofield P, Diggens J, Charleson C, et al. (2010) Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians. Pat Edu Couns 79(2):143–151CrossRef
8.
go back to reference Yap KY, Kuo EY, Lee JJJ, et al. (2010) An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer 18(7):883–891CrossRefPubMed Yap KY, Kuo EY, Lee JJJ, et al. (2010) An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer 18(7):883–891CrossRefPubMed
10.
go back to reference Lo Re M, Schmidt S, Güthlin C (2012) Translation and adaptation of an international questionnaire to measure usage of complementary and alternative medicine (I-CAM-G). BMC Complement Altern Med 12(1):259. doi:10.1186/1472-6882-12-259 CrossRef Lo Re M, Schmidt S, Güthlin C (2012) Translation and adaptation of an international questionnaire to measure usage of complementary and alternative medicine (I-CAM-G). BMC Complement Altern Med 12(1):259. doi:10.​1186/​1472-6882-12-259 CrossRef
12.
go back to reference Oevermann U (2001) Zur Analyse der Struktur von sozialen Deutungsmustern (1973) [Analysis of the structure of social reference patterns]. Sozialer Sinn 1:3–34 Oevermann U (2001) Zur Analyse der Struktur von sozialen Deutungsmustern (1973) [Analysis of the structure of social reference patterns]. Sozialer Sinn 1:3–34
13.
go back to reference Broom A, Adams J (2009) Oncology clinicians’ accounts of discussing complementary and alternative medicine with their patients. Health (London) 13(3):317–336CrossRef Broom A, Adams J (2009) Oncology clinicians’ accounts of discussing complementary and alternative medicine with their patients. Health (London) 13(3):317–336CrossRef
17.
go back to reference Burstein HJ (2000) Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol 18(13):2501–2504PubMed Burstein HJ (2000) Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol 18(13):2501–2504PubMed
Metadata
Title
Oncologists’ experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis
Authors
Güthlin Corina
Holmberg Christine
Gudrun Klein
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3205-3

Other articles of this Issue 9/2016

Supportive Care in Cancer 9/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine